CPhI Annual Report expert sees CDMOs as potentially a source of process innovation but warns both regulator and license holders need to move past regulatory diktats.
CPhI Worldwide experts make pharma predictions for 2017: Orphan drugs, CMO continuous manufacturing and developing world sales offer the biggest revenue opportunities in pharma.